ClinicalTrials.gg
DrugRead study by study

Pelacarsen clinical trials

Also written TQJ230.

Includes 4 studies of Pelacarsen sodium.

studies test it
17
open now
1
in phase 3
8
first study started
2015
ClinicalTrials.gov finds 14 studies for pelacarsen. How that becomes 17 here

Every study that search finds has been read, to see whether and how it gives pelacarsen. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 14Found by its intervention search · See all 14 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 13 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. +4Give it under a name that search misses: a biosimilar’s code or a misspelling
  3. 18Give pelacarsen to participants
  4. −1Observe patients on it, or give it outside a trial
  5. 17Test it: the count on this site

Get an email when these change. Save the pelacarsen studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Pelacarsen
6
Pelacarsen (TQJ230)
3

Development codes

TQJ230
11
ISIS 681257
1

Other names

AKCEA-APO(a)-LRx
1
IONIS-APO(a)-LRx
1

Studies by the year they started

17 studies that test it; most in 2017 (3)

Studies that test pelacarsen, by start year
YearStudies
20151
20173
20182
20191
20212
20221
20231
20242
20252
20262

By phase

A phase 1/2 study counts in both.

Phase 1
6
Phase 2
2
Phase 3
8
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 16 · Other 1

Novartis Pharmaceuticals (10) · Akcea Therapeutics (4) · Ionis Pharmaceuticals, Inc. (2) · University Medical Centre Ljubljana (1)

Often tested with

Tested in the same studies.

Inclisiran (1) · Warfarin (1) · Clopidogrel (1)

Studies

Open first, then newest update. How each study uses pelacarsen has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 17

Tested on its own · 14 — no other medicine in its arm
Tested in a combination · 3 — another drug in the study is under test too
Observed · 1 — patients on it are followed, or it is given outside a trial

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call pelacarsen · ClinicalTrials.gg INT002089

  • MeSH (NLM) C000730804pelacarsenOne source ClinicalTrials.gov
  • UNII (FDA) LSO9H7UZ90PELACARSENOne source FDA
  • NCI Thesaurus C174676PelacarsenOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion